PDCD1 and hepatocellular carcinoma: Additionally, in hepatocellular carcinoma cell resistance-related studies, circMET,can drive hepatocellular carcinoma immunosuppression and anti-PD-1 therapy resistance via the miR-30-5p/Snail/DPP4 axis.